Physician profile
Igor Volkov
NPI 1588810162
$9,842.69
in general payments reported to CMS, 2019-2025
12 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $129 · 2021: $41.57 · 2022: $920 · 2023: $2,009 · 2024: $3,343 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,154 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,153.67 |
| Education | $250.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,081.18 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Alkermes, INC. | $1,499.10 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,444.42 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $1,104.46 | 2021-2025 | Invega Sustenna, Invega Trinza, Invega |
| Neurocrine Biosciences, INC. | $912.98 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $727.33 | 2024-2025 | Fanapt |
| Abbvie INC. | $726.22 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $622.93 | 2024-2025 | Cobenfy |
| Allergan, INC. | $488.86 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $138.76 | 2024 | Caplyta |
| Lundbeck LLC | $50.89 | 2019-2023 | Abilify Maintena |
| Indivior INC. | $45.56 | 2024 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Volkov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.